Phase 2 Pancreatic Cancer Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

For the colorectal cancer group:

• Adults aged 18 or older (or the legal age of consent in the country where the trial is taking place)
• People with a confirmed diagnosis of advanced colon or rectal cancer that cannot be surgically removed, either because it has spread locally or to other parts of the body
• People who have received at least 1 but no more than 2 prior systemic treatments for advanced colorectal cancer, with confirmed evidence that the cancer has progressed on the most recent treatment
• People who are able to provide a tumor tissue sample, either from a new biopsy or from a previously stored sample

For the pancreatic cancer group:

• People with a confirmed diagnosis of advanced pancreatic cancer that cannot be surgically removed, either because it has spread locally or to other parts of the body
• People who have received exactly 1 prior line of treatment for advanced pancreatic cancer, with confirmed evidence of disease progression
• People who are able to provide a tumor tissue sample at the start of the trial, where this is available and medically appropriate

For all participants:

• People who have at least one measurable area of cancer that can be tracked during the trial, as assessed by the study team
• People who are willing to use adequate contraception during the trial
• People who are able to understand and agree to the trial requirements
• People with a good general level of physical functioning — specifically, an ECOG performance status of 0 (fully active) or 1 (restricted in physically strenuous activity but able to carry out light work) (confirm with trial site)
• People whose major organs such as the liver, kidneys, and blood system are functioning adequately

Who may not be able to join:

• People who have had another cancer (other than the one being studied) that has been active or required treatment in the past 2 years — with the exception of certain treated skin cancers or early-stage cancers that were fully removed with no signs of return
• People who have had major surgery within 28 days before entering the trial
• People who have previously had a bone marrow transplant or a solid organ transplant (such as a kidney or liver transplant)
• People who have a known allergy or sensitivity to the study treatment or its ingredients
• People with severe, uncontrolled, or currently active heart or blood vessel problems
• People with serious or poorly controlled high blood pressure
• People who have had significant bleeding or bleeding problems within the past month
• People who have had a serious infection within the past 4 weeks
• People with a currently active infection that requires ongoing treatment, or who have a known HIV diagnosis
• People who have had a serious blood clot event — such as a deep vein thrombosis or a blood clot in the lungs — within the past 3 months
• People who have cancer that has spread to the brain or central nervous system and has not been treated, or where the brain/CNS disease has continued to progress
• People who currently have lung inflammation (pneumonitis), or who have a history of pneumonitis that required steroids or immune-modifying treatment within the past 90 days, or any history of drug-induced pneumonitis
• People who have an autoimmune disease that required ongoing systemic treatment within the past 2 years
• People with any active kidney condition, including infection, the need for dialysis, or any other significant kidney problem
• People who still have side effects from previous cancer treatment that have not returned to a mild level (Grade 1) or to how they were before that treatment
• People with serious or unstable physical or mental health conditions that could interfere with safely participating in the trial
• People with significant liver disease, such as cirrhosis with complications including fluid build-up in the abdomen, confusion related to liver function, abnormal blood clotting, or persistent jaundice
• People who test positive for Hepatitis B at the start of the trial or within 3 months before the first dose
• People who test positive for Hepatitis C antibodies or active Hepatitis C infection at the start of the trial or within 3 months before the first dose
• People who have received immune-suppressing medications within the past 30 days, or who need long-term immune suppression
• People who have previously been treated with a specific type of targeted drug called an antibody-drug conjugate (ADC) that uses a TOPO1-inhibitor payload (confirm with trial site)
• People who have received a live vaccine within 30 days before entering the trial
• People who are currently in another clinical trial or who have received an experimental treatment within the past 4 weeks
• People who are pregnant or breastfeeding
• People who are unable to follow the trial schedule and required visits, including the follow-up period

Important: Always verify eligibility with the trial site directly before applying.